December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

18.73 USD +3.87 (+26.04%)
Official Closing Price Updated: 7:59 PM EST, Jan 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aurinia Pharm Ord

< Previous 1 2 3 4 5 6 7 8 Next >
Aurinia Announces Results of Annual General Meeting
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the nine incumbent directors of the Company were elected at the Company’s annual general... 
From Business Wire News Releases
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during... 
From Business Wire News Releases
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today... 
From Business Wire News Releases
Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during... 
From Business Wire News Releases
Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent... 
From Business Wire News Releases
Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020
Aurinia to Report 1Q20 Results on May 14, 2020 
From Business Wire News Releases
Aurinia Appoints Joe Miller as Chief Financial Officer
Aurinia Appoints Joe Miller as Chief Financial Officer 
From Business Wire News Releases
Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today... 
From Business Wire News Releases
venBio Closes $394 Million Life Sciences Venture Capital Fund
venBio Closes $394 Million Life Sciences Venture Capital Fund, Bringing Total Assets Under Management to Nearly $1 Billion 
From Business Wire News Releases
Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings
NKF 2020 Spring Clinical Meetings Late-Breaking Presentation Announcement 
From Business Wire News Releases
Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland
Aurinia established U.S. Center of Commercial Operations in Rockville, MD 
From Business Wire News Releases
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced... 
From Business Wire News Releases
Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) , a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and... 
From Business Wire News Releases
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS 
From Business Wire News Releases
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after the... 
From Business Wire News Releases
Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today... 
From Business Wire News Releases
Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual... 
From Business Wire News Releases
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today... 
From Business Wire News Releases
Biotech Advancements In The Immuno-Oncology Field For Pediatric and Adult Brain Tumors
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Advancements in the Immuno-Oncology Field for Pediatric and Adult Brain Tumors
Financialnewsmedia.com News Commentary 
From PR Newswire
Aurinia Prices US$166.7 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today... 
From Business Wire News Releases
Aurinia Announces Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today... 
From Business Wire News Releases
IIROC Trade Resumption - AUP
From PR Newswire
IIROC Trading Halt - AUP
From PR Newswire
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and... 
From Business Wire News Releases
Hepion Pharmaceuticals Announces Canadian Research Team’s Academic Appointments
From ACCESSWIRE
Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and... 
From Business Wire News Releases
Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today... 
From Business Wire News Releases
Aurinia Announces Updates to the Board of Directors
Aurinia Announces Updates to the Board of Directors 
From Business Wire News Releases
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil
Aurinia Completes Voclosporin Drug-drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.